RYTM

RHYTHM PHARMACEUTICALS, INC.

7 filings tracked

healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bearishMay 5

Net loss widened to $55.6 million in Q1 2026.

earnings miss

60%

bearishMay 5

SG&A expenses increased 63% YoY, outpacing revenue growth.

margin compression

70%

bearishMay 5

High-cost deferred royalty obligation of $108.5M with 17.1% effective interest.

debt restructure

80%

bullishMay 5

Product revenue surged 59% YoY following aHO label expansion.

guidance raise

90%

bearishMay 5

Net loss widened to $55.6 million in Q1 2026.

earnings miss

60%

bearishMay 5

SG&A expenses increased 63% YoY, outpacing revenue growth.

margin compression

70%

bearishMay 5

High-cost deferred royalty obligation of $108.5M with 17.1% effective interest.

debt restructure

80%

bullishMay 5

Product revenue surged 59% YoY following aHO label expansion.

guidance raise

90%

bearishMay 5

Net loss widened to $55.6 million in Q1 2026.

earnings miss

60%

bearishMay 5

SG&A expenses increased 63% YoY, outpacing revenue growth.

margin compression

70%

bearishMay 5

High-cost deferred royalty obligation of $108.5M with 17.1% effective interest.

debt restructure

80%

bullishMay 5

Product revenue surged 59% YoY following aHO label expansion.

guidance raise

90%

bearishMay 5

Net loss widened to $55.6 million in Q1 2026.

earnings miss

60%

bearishMay 5

SG&A expenses increased 63% YoY, outpacing revenue growth.

margin compression

70%

bearishMay 5

High-cost deferred royalty obligation of $108.5M with 17.1% effective interest.

debt restructure

80%

bullishMay 5

Product revenue surged 59% YoY following aHO label expansion.

guidance raise

90%

bearishMay 5

Net loss widened to $55.6 million in Q1 2026.

earnings miss

60%

bearishMay 5

SG&A expenses increased 63% YoY, outpacing revenue growth.

margin compression

70%

bearishMay 5

High-cost deferred royalty obligation of $108.5M with 17.1% effective interest.

debt restructure

80%

bullishMay 5

Product revenue surged 59% YoY following aHO label expansion.

guidance raise

90%

bearishMay 5

Net loss widened to $55.6 million in Q1 2026.

earnings miss

60%

bearishMay 5

SG&A expenses increased 63% YoY, outpacing revenue growth.

margin compression

70%

bearishMay 5

High-cost deferred royalty obligation of $108.5M with 17.1% effective interest.

debt restructure

80%

bullishMay 5

Product revenue surged 59% YoY following aHO label expansion.

guidance raise

90%

bearishMay 5

Net loss widened to $55.6 million in Q1 2026.

earnings miss

60%

bearishMay 5

SG&A expenses increased 63% YoY, outpacing revenue growth.

margin compression

70%

bearishMay 5

High-cost deferred royalty obligation of $108.5M with 17.1% effective interest.

debt restructure

80%

bullishMay 5

Product revenue surged 59% YoY following aHO label expansion.

guidance raise

90%

Filing History

10-QMay 5, 2026

The Q1 2026 filing reveals a company at a crossroads: it possesses a validated, high-growth product in IMCIVREE but is struggling to translate that success into a sustainable financial model. The label expansion into acquired hypothalamic obesity is a definitive win that validates the company's precision medicine approach, yet the widening losses and the weight of high-interest royalty debt create a volatile risk profile for investors. The overall impact of the filing is a mixture of commercial optimism and financial caution. While the revenue trajectory is impressive, the failure of the EMANATE trial removes a key catalyst for near-term growth and places immense pressure on the successful launch of the aHO indication. Investors must now weigh the potential of a global obesity platform against the reality of a high-burn rate and a complex capital structure that prioritizes preferred shareholders and royalty holders over common equity.